"There is no place in the world that brings together such a strong emphasis on basic Biology with dedicated and experienced drug discoverers like Genentech."
I began my industrial career in 2003 working at Neurocrine Biosciences after completing a Ph.D. at the University of Virginia and a postdoctoral fellowship at Rockefeller University where I focused on the molecular characterization of G protein-coupled receptors. This first entry point into industry afforded me a great opportunity to integrate my academic training into the applied world of drug discovery and is where I began to hone my skills as a small molecule drug hunter. In 2007 I moved to Genentech to the department of Biochemical and Cellular Pharmacology where I’ve had the pleasure of working with some of the smartest scientists in the world attempting to discover novel small molecule modulators of diverse targets with the prospect of helping treat patients afflicted with life altering diseases. This work has spanned across multiple therapeutic areas with my most recent efforts focused on supporting and advancing the discovery of novel classes of antibiotics meant to treat infections caused by multi-drug resistant bacteria.
I am fortunate to work with a group of highly talented in vitro pharmacologists whose technical expertise spans from card-carrying enzymology to ion channel electrophysiology to native cell biology. We are united with a common mission to apply each of these specialties to develop robust assays that facilitate the discovery and characterization of small molecules capable of reducing complex systems into quantitative readouts. We work as integral members of multi-disciplinary project teams spanning all of the therapeutic areas of interest at Genentech.
My own lab’s focus has recently centered on the discovery of novel mechanistic classes of antibiotics. I lead one of these particular project teams comprised of people from diverse functions who are all working towards a common goal. I take very seriously the role that a team leader can play to ensure full engagement of each person to make the team more wholly effective. Together we can work towards the ultimate goal of slowing the spread of antibiotic resistance by bringing to patients new therapeutic modalities.